Filing Details

Accession Number:
0001209191-20-018258
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-11 19:07:19
Reporting Period:
2020-03-09
Accepted Time:
2020-03-11 19:07:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1503802 Karyopharm Therapeutics Inc. KPTI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1364719 Michael Kauffman C/O Karyopharm Therapeutics Inc.
85 Wells Avenue
Newton MA 02459
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-10 10,000 $4.75 565,122 No 4 M Direct
Common Stock Disposition 2020-03-10 7,932 $22.11 557,190 No 4 S Direct
Common Stock Disposition 2020-03-10 2,068 $22.64 555,122 No 4 S Direct
Common Stock Acquisiton 2020-03-09 10,000 $4.75 766,489 No 4 M Indirect By Spouse
Common Stock Disposition 2020-03-09 7,000 $22.58 759,489 No 4 S Indirect By Spouse
Common Stock Disposition 2020-03-09 3,000 $22.38 756,489 No 4 S Indirect By Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Indirect By Spouse
No 4 S Indirect By Spouse
No 4 S Indirect By Spouse
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-03-10 10,000 $0.00 10,000 $4.75
Common Stock Stock Option (right to buy) Disposition 2020-03-09 10,000 $0.00 10,000 $4.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
366,061 2023-09-02 No 4 M Direct
410,303 2023-09-02 No 4 M Indirect
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.57 to $22.55, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.575 to $22.76, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
  5. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.095 to $23.04, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  6. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.05 to $23.75, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  7. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.